These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 12505691)

  • 1. In vivo imaging of the brain cannabinoid receptor.
    Gifford AN; Makriyannis A; Volkow ND; Gatley SJ
    Chem Phys Lipids; 2002 Dec; 121(1-2):65-72. PubMed ID: 12505691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, structure-activity relationship, and evaluation of SR141716 analogues: development of central cannabinoid receptor ligands with lower lipophilicity.
    Katoch-Rouse R; Pavlova OA; Caulder T; Hoffman AF; Mukhin AG; Horti AG
    J Med Chem; 2003 Feb; 46(4):642-5. PubMed ID: 12570386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging the brain marijuana receptor: development of a radioligand that binds to cannabinoid CB1 receptors in vivo.
    Gatley SJ; Lan R; Volkow ND; Pappas N; King P; Wong CT; Gifford AN; Pyatt B; Dewey SL; Makriyannis A
    J Neurochem; 1998 Jan; 70(1):417-23. PubMed ID: 9422389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxyl ic acid phenylamide (CP-272871) for the CB(1) cannabinoid receptor.
    Meschler JP; Kraichely DM; Wilken GH; Howlett AC
    Biochem Pharmacol; 2000 Nov; 60(9):1315-23. PubMed ID: 11008125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular interaction of the antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1- (2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide with the CB1 cannabinoid receptor.
    Shim JY; Welsh WJ; Cartier E; Edwards JL; Howlett AC
    J Med Chem; 2002 Mar; 45(7):1447-59. PubMed ID: 11906286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of the CB1 selective cannabinoid antagonist AM281: a potential human SPECT ligand.
    Lan R; Gatley J; Lu Q; Fan P; Fernando SR; Volkow ND; Pertwee R; Makriyannis A
    AAPS PharmSci; 1999; 1(2):E4. PubMed ID: 11741201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors.
    MacLennan SJ; Reynen PH; Kwan J; Bonhaus DW
    Br J Pharmacol; 1998 Jun; 124(4):619-22. PubMed ID: 9690851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analogs of JHU75528, a PET ligand for imaging of cerebral cannabinoid receptors (CB1): development of ligands with optimized lipophilicity and binding affinity.
    Fan H; Kotsikorou E; Hoffman AF; Ravert HT; Holt D; Hurst DP; Lupica CR; Reggio PH; Dannals RF; Horti AG
    Eur J Med Chem; 2009 Feb; 44(2):593-608. PubMed ID: 18511157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists.
    Lan R; Liu Q; Fan P; Lin S; Fernando SR; McCallion D; Pertwee R; Makriyannis A
    J Med Chem; 1999 Feb; 42(4):769-76. PubMed ID: 10052983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors.
    Petitet F; Jeantaud B; Reibaud M; Imperato A; Dubroeucq MC
    Life Sci; 1998; 63(1):PL1-6. PubMed ID: 9667767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors.
    Gatley SJ; Gifford AN; Volkow ND; Lan R; Makriyannis A
    Eur J Pharmacol; 1996 Jul; 307(3):331-8. PubMed ID: 8836622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor.
    Hurst DP; Lynch DL; Barnett-Norris J; Hyatt SM; Seltzman HH; Zhong M; Song ZH; Nie J; Lewis D; Reggio PH
    Mol Pharmacol; 2002 Dec; 62(6):1274-87. PubMed ID: 12435794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional consequences of the acute administration of the cannabinoid receptor antagonist, SR141716A, in cannabinoid-naive and -tolerant animals: a quantitative 2-[14C]deoxyglucose study.
    Freedland CS; Whitlow CT; Smith HR; Porrino LJ
    Brain Res; 2003 Feb; 962(1-2):169-79. PubMed ID: 12543468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 11C-JHU75528: a radiotracer for PET imaging of CB1 cannabinoid receptors.
    Horti AG; Fan H; Kuwabara H; Hilton J; Ravert HT; Holt DP; Alexander M; Kumar A; Rahmim A; Scheffel U; Wong DF; Dannals RF
    J Nucl Med; 2006 Oct; 47(10):1689-96. PubMed ID: 17015906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel pyrazole cannabinoids: insights into CB(1) receptor recognition and activation.
    Wiley JL; Jefferson RG; Grier MC; Mahadevan A; Razdan RK; Martin BR
    J Pharmacol Exp Ther; 2001 Mar; 296(3):1013-22. PubMed ID: 11181936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain.
    Adams IB; Compton DR; Martin BR
    J Pharmacol Exp Ther; 1998 Mar; 284(3):1209-17. PubMed ID: 9495885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 'One-trial sensitization' to the anxiolytic-like effects of cannabinoid receptor antagonist SR141716A in the mouse elevated plus-maze.
    Rodgers RJ; Haller J; Halasz J; Mikics E
    Eur J Neurosci; 2003 Mar; 17(6):1279-86. PubMed ID: 12670316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain.
    Rinaldi-Carmona M; Pialot F; Congy C; Redon E; Barth F; Bachy A; Brelière JC; Soubrié P; Le Fur G
    Life Sci; 1996; 58(15):1239-47. PubMed ID: 8614277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of cannabinoid receptors coupled to vasorelaxation by endothelium-derived hyperpolarizing factor.
    Harris D; Kendall DA; Randall MD
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Jan; 359(1):48-52. PubMed ID: 9933150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positron emission tomographic imaging of the cannabinoid type 1 receptor system with [¹¹C]OMAR ([¹¹C]JHU75528): improvements in image quantification using wild-type and knockout mice.
    Herance R; Rojas S; Abad S; Jiménez X; Gispert JD; Millán O; Martín-García E; Burokas A; Serra MÀ; Maldonado R; Pareto D
    Mol Imaging; 2011 Dec; 10(6):481-7. PubMed ID: 22201539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.